Please assess the completion status of the following clinical trial:

Trial Title: Maintenance Study of Certolizumab Pegol (CZP) in Crohn's Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who participated in main double-blind induction study C87037 (NCT00291668) and showed clinical efficacy~Exclusion Criteria:~* Subjects who experienced aggravation of Crohn's disease during main double-blind induction study C87037 (NCT00291668) and required treatment change

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- CZP 400 mg / Placebo (Type: EXPERIMENTAL): Certolizumab pegol (CZP) 400 mg in this extension study / Placebo in double-blind main study (NCT00291668)
- CZP 400 mg / CZP 200 mg (Type: EXPERIMENTAL): Certolizumab pegol (CZP) 400 mg in this extension study / Certolizumab pegol (CZP) 200 mg in double-blind main study (NCT00291668)
- CZP 400 mg / CZP 400 mg (Type: EXPERIMENTAL): Certolizumab pegol (CZP) 400 mg in this extension study / Certolizumab pegol (CZP) 400 mg in double-blind main study (NCT00291668)

Based on this trial design, predict the completion outcome and termination type (if applicable).